NEJM stands by its criticism of Vioxx study.
Tanne
Janice Hopkins
JH
D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced*; D010506:Periodicals as Topic; D012107:Research Design; D012307:Risk Factors; D013450:Sulfones / Q000009:adverse effects*
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib